IGNT-News Out

[mickymoose99]

Ingen Announces Projections of $10M in Sales for 2010

YUCAIPA, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.

With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.

With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.

"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.









About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at

[mickymoose99]

Ingen Receives $100K Purchase Order Today for New Oxyview Nasal Cannula


Sales and Demand for New Products Continue to Increase
YUCAIPA, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview Nasal Cannulas in value of $100,000.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA has resulted in an increase of buyers for Ingen's new Oxyview Nasal Cannula. The company now provides 8 different models of the Oxyview and Oxyview Nasal Cannula. The cannulas are designed for Adults, Pediatrics and Infants, and include 0-6 liters/minute and a low-flow 0-3 liters/minute unit that is either reusable or comes attached to a high quality 7' latex free oxygen tube with a curved soft-tip nasal cannula. The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow rate readings for the patient and caregiver.

The company also received very good news today from the COPD Foundation. The November issue of COPD Digest has been printed and shipped and is receiving an excellent response at the American College of Chest Physician's Annual 2009 conference in San Diego, CHEST 2009. Ingen has a full-page color ad in this edition of the COPD Digest and telephone orders and PayPal orders have increased this week.

"We are seeing a strong increase in revenues, and expect this trend to continue over the next several years. Our accountants and auditors are diligently working on completion of the SEC filings, specifically the 10-KSB. We anticipate filing a revised annual and quarterly report on the OTC Pink Sheets later next week. The company is progressing forward very nicely at this time and we will continue to make public announcements as each event occurs," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.







About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch, as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, according to the World Health Organization. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire,

SOURCE: Ingen Technologies, Inc.

[mickymoose99]

IGNT moving on the ask .
volume 64 million and is over the ten day avg
RSI LINE is the same at 44.60 but starting to show a nice curve
MACD is even
keep your eye on it , getting into good position
COULD BE LOOKING AT A NICE JUMP

[Chuck.W]

IGNT Igen Technologies, INC.
IGNT still looking good with lots of volume today at 88mil. now.
Possible news out after close could mean a Great run for tomorrow.IMO.
Keep this one on your radar. Good luck to all

[fordf250]

ignt ceo interview, tune in to moneychannel. im expecting news this morning... cannot wait.

[mickymoose99]

Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase


CEO Live Radio Broadcast Talks About These New Markets
YUCAIPA, Calif., Nov 20, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.
According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.

The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 - 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas.

"Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies," stated Scott Sand, Chief Executive Officer and Chairman of the Board.











About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants, with issued patents in China and the USA, and pending patents in Japan, Canada and European Communities expected to be issued in 2010. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

[Chuck.W]

IGNT Ingen Technologies, Inc.

Charts look good this morning
RSI 44.42 heading towards bullish
Mac D and signal line running steady

Should be another great week for IGNT. IMO.
Good luck to all!!!!

[stocksamongus]

LOOKS HOT IMO!!!!

[stocksamongus]

I was over looking the charts this morning and the pattern indicates it could head upward, obviously just IMO but still it would be a smart idea to keep an eye on. The company produces extremely important respirsatory devices which are always in high demand; people need them every day. I'm pretty confident the company will create high revenue and profit for people such as myself and you!!!

[trading_guy]

IGNT is having another great day today!! The RSI line is moving northward and it is at 49.30. The price is at .003 and by the way this stock is trading look for price increases throughout the day. The MAC-D line is above the signal line and curving northward. I think IGNT is gonna do extremly well today IMO....Happy Trading !!!

[johnsis80]

--------------------------------------------------------------------------------

IGNT - Tradeing with high volume today!!!
This is one to watch!!! RSI LINE approaching Bullish - Mac D running even

This leading medical device manufacture that is focused on the $4B respiratory market with their oxyview products for the growing ageing population & emerging markets for home.

A growing elderly popuulation increase in home oxygen therapy & surgeries, & an increase in chronic obstructive pulmonary dieseases in the USA has resulted in an increase of buyers for Ingen

[mickymoose99]

IGNT

+ 3.57 % recovering from the dip earlier today

RSI LINE @ 46.97 and starting to rise

HIST GRAM starting to build

SLOPE is also starting to rise

With IGNT entering the hospital and therapy markets

I believe its only a matter of time before we see IGNT

Take off ,

[mickymoose99]

Photo Release -- Ingen at Home Plate Ready to Catch Sales of $10M in 2010 and $50M in 2012

YUCAIPA, Calif., Nov 23, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that expected sales projections for 2010 and 2012 are on target.
Photos accompanying this release are available at and

The company's ISO Certification in December 2009 also allows Ingen to begin shipping product of its new Oxyview Nasal Cannula and Oxyview to China, Europe, Australia, Japan and Canada. Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M.The company's ISO consultant, Emergo Consulting Group, is assisting with both the ISO and CE Mark, as well as introducing these products to their distribution partners for export in these countries.

In addition to ISO Certification, the company expects to have in place its GSA contract with various government sectors including VA Hospitals and the Department of Defense in 3-4 weeks.

"Emergo Consulting Group will provide us with the outcome of the MEDICA exhibit in Germany, and this will be provided in a news release later this week. The Oxyview Nasal Cannula has received serious interest from institutional buyers, oxygen providers and suppliers, and patients. Sales have been made to all of these sectors in the past 2 months, and interest continues to grow," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

[stockjock]

Thanks for the new news! Interest in this company continues to be progressive. Imo, once the GSA contract is solidified there will be no stopping this company!!!

[fordf250]

Ingen Debuts Oxyview Nasal Cannula to 30,000 Hospital and Respiratory Managers
CEO Live Radio Broadcast Talks About the AARC Convention

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EST, Thursday December 3, 2009
Buzz up! 0 Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Dec. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is an exhibitor at the American Association of Respiratory Care (AARC) 55th international respiratory congress in San Antonio-Texas this coming weekend. Further, CEO Scott Sand, will discuss the AARC exhibition today, December 3, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.0026 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The Oxyview Nasal Cannula is the new generation of oxygen delivery equipment being introduced at this year's annual meeting for the American Association for Respiratory care. Ingen stands to close several institutional contracts representing a handsome market-share of the annual $200M oxygen cannula market. The Oxyview Nasal Cannula uses the new patented "gravity-independent" technology and is secured by several U.S. and Foreign patents.



Since 1947, the American Association for Respiratory Care (AARC) has been committed to enhancing professionalism as a respiratory care practitioner, improving performance on the job, and helping to broaden the scope of knowledge essential to the clinician's success. With more than 47,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.



The company introduced the Oxyview Nasal Cannula at last month's MEDICA convention in Germany, leaving with 6 major distributors interested in the new device. The company is bringing a close to its ISO certification this month in order provide product to these new distributors outside the USA.



"Ingen will update the Pink Sheets annual and quarterly report next week in order to bring current reporting obligations with the OTC Pink Sheets. Further, the SEC has responded to our proposal regarding the completion of our required reporting obligations, and the company can now complete the various 10-Q and 10-KSB filings in the next 60 days. This should build confidence with existing and new shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



















About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

[fordf250]

Pinnacle Digest: Ingen Tech Recieves New Distribution Partners : Thoughts?

Dec 21, 2009 (M2 PRESSWIRE via COMTEX) -- is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that the company has received new distribution partners and made sales at the American Association of Respiratory Care (AARC) 55th international respiratory congress, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.

[RAZOR11]

YUCAIPA, Calif., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that they have signed a Supply Agreement with Amsino International Inc. on December 1, 2009.



The Pomona-California based Amsino was established in 1993 and is a leading medical device developer and manufacturer dedicated to advancing healthcare worldwide by developing, manufacturing, and marketing medical products that help improve the safety and effectiveness of patient care. Amsino's product and service portfolio includes infusion products and access devices, blood collection and transfusion devices, anesthesia and surgical products, urological products, enteral feeding and irrigation products, respiratory therapy products, patient care products, and a full-service contract manufacturing business. Amsino products are distributed in the United States and more than 30 other countries worldwide.



Ingen and Amsino will manufacture the Oxyview and Oxyview Nasal Cannula at a reduced cost compared to current manufacturing costs. The Supply Agreement is effective for a 3-year term and is renewable.



Ingen is ready for ISO 13485 Certification and is now waiting in line for an audit date in January-2010. The company expects to be certified and the CE Mark and distribution of product will follow. The company expects GSA approval and will make an announcement in January. Both ISO certification and GSA will expand product distribution to U.S. Government branches, inclusive of the Department of Defense and the VA Hospital network, as well as export to China, Japan, Canada, Australia and Europe.



"We look forward to working with Richard Lee, CEO of Amsino, and his professional team. This agreement allows Ingen to reduce manufacturing costs by 40%, and increase efficiency and quality of our respiratory product line. Amsino International was introduced to us through Pacific Pearl Group, our Investment Banking consultants, who have evaluated Amsino as a good fit for manufacturing and distribution of the Ingen product line. With ISO certification near completion and GSA close to approval, the relationship between Amsino and Ingen is expected to be a prosperous one," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

[Chuck.W]

Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Another Giant Leap for Ingen

.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Wednesday January 6, 2010, 1:36 pm

YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.



A photo accompanying this release is available at



The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.



This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.



"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

[fordf250]

Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Another Giant Leap for Ingen


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0026 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Wednesday January 6, 2010, 1:36 pm EST

YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.



A photo accompanying this release is available at



The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.



This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.



"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.











About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

[johnbeckham]

IGNT- NEWS OUT YESTERDAY LOOKS GOOD. NEW VERY INEXPENSIVE PULSE OXIMETER. I BELIEVE THIS STOCK HAS HIT IT'S LOW AND IS ABOUT TO BOUNCE BACK AND MAKE A BIG RUN.